Dimethyl fumarate: clinical use
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Dimethyl fumarate: clinical use. Dimethyl fumarate activates the nuclear-related factor 2 transcriptional pathway. Fully referenced neurology checklist.
Mode of action
- Dimethyl fumarate activates the nuclear-related factor 2 transcriptional pathway
- This inhibits the entrance of neutrophils into the central nervous system
Dosing
Locked: subscribe to see this section.
Precautions
Locked: subscribe to see this section.
Indications to stop treatment
Locked: subscribe to see this section.
Risk factors for relapse after switching from Natalizumab
Locked: subscribe to see this section.
Predictors of clinical response
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis – a review of approved medications. Eur J Neurol 2016; 23(Suppl 1):18-27.
- Hutchinson M, Fox RJ, Hardova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014; 30:613-627.
- Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. NEJM 2012; 367:1098–1107.
- Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. NEJM 2012; 367:1087–1097.
- Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Health Drug Benefits 2015; 8:448-453.
- And 6 more. Subscribe to see the full list
